Single dose of empagliflozin increases in vivo cardiac energy status in diabetic db/db mice

Cardiovasc Res. 2018 Dec 1;114(14):1843-1844. doi: 10.1093/cvr/cvy246.

Authors

Desiree Abdurrachim¹, Emmy Manders¹, Klaas Nicolay¹, Eric Mayoux², Jeanine J Prompers^{1

3}

Affiliations

¹ Department of Biomedical Engineering, Biomedical NMR, Eindhoven University of Technology, Eindhoven, The Netherlands.
² Boehringer Ingelheim Pharma, Cardiometabolic Diseases Research, Biberach an der Riss, Germany.
³ Department of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands.

PMID: 30295756
DOI: 10.1093/cvr/cvy246

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adenosine Triphosphate / metabolism
Animals
Benzhydryl Compounds / administration & dosage*
Blood Glucose / drug effects*
Blood Glucose / metabolism
Diabetes Mellitus / diagnostic imaging
Diabetes Mellitus / drug therapy*
Diabetes Mellitus / genetics
Diabetes Mellitus / metabolism
Disease Models, Animal
Energy Metabolism / drug effects*
Glucosides / administration & dosage*
Ketones / blood
Magnetic Resonance Imaging
Magnetic Resonance Spectroscopy
Male
Mice, Inbred C57BL
Myocytes, Cardiac / drug effects*
Myocytes, Cardiac / metabolism
Myocytes, Cardiac / pathology
Phosphocreatine / analogs & derivatives
Phosphocreatine / metabolism
Sodium-Glucose Transporter 2 Inhibitors / administration & dosage*
Ventricular Function / drug effects

Substances

Benzhydryl Compounds
Blood Glucose
Glucosides
Ketones
Sodium-Glucose Transporter 2 Inhibitors
Phosphocreatine
phosphocreatinine
Adenosine Triphosphate
empagliflozin